The biosynthesis of rebeccamycin, an antitumor compound, involves the remarkable eight-electron oxidation of chlorinated chromopyrrolic acid. Although one rebeccamycin biosynthetic enzyme is capable of generating low levels of the eight-electron oxidation product on its own, a second protein, RebC, is required to accelerate product formation and eliminate side reactions. However, the mode of action of RebC was largely unknown. Using crystallography, we have determined a likely function for RebC as a flavin hydroxylase, captured two snapshots of its dynamic catalytic cycle, and trapped a reactive molecule, a putative substrate, in its binding pocket. These studies strongly suggest that the role of RebC is to sequester a reactive intermediate produced by its partner protein and to react with it enzymatically, preventing its conversion to a suite of degradation products that includes, at low levels, the desired product.flavin enzymes ͉ x-ray crystallography ͉ indolocarbazoles ͉ antitumor R ebeccamycin (1, Fig. 1a) is a natural product isolated from Lechevalieria aerocolonigenes (1) and is a prototype for a class of compounds that bind to DNA-topoisomerase I complexes (2), preventing the replication of DNA and thereby acting as antitumor compounds (3). Rebeccamycin is synthesized by the action of eight enzymes, with the overall conversion of Ltryptophan, chloride, molecular oxygen, glucose, and a methyl group to the glycosylated indolocarbazole rebeccamycin (1) (4-9). One step in this pathway is the conversion of chlorinated chromopyrrolic acid (2) to the rebeccamycin aglycone (3); this reaction involves an eight-electron oxidation, and it is carried out by the enzyme pair RebP and RebC (10). The mechanism of this reaction is not established (8).RebP is annotated as a cytochrome P450, and it is functionally equivalent to its homologue StaP from the staurosporine biosynthetic pathway (10), which has been used in place of RebP in initial biochemical investigations. Additionally, all biochemical work on StaP and RebC has used nonchlorinated substrates because they are well tolerated by both enzymes (8). One of the most remarkable features of StaP is that when it is incubated alone with its nonchlorinated substrate, chromopyrrolic acid (4), as well as with an electron source (provided by ferredoxin, flavodoxin NADP ϩ -reductase, and NAD(P)H), StaP is capable of generating a number of products, including arcyriaflavin A (5), 7-hydroxy-K252c (6), and K252c (7) at a 1:7:1 ratio (8) (Fig. 1b). Inclusion of RebC, an FAD-containing protein, in the reaction mixture results in near-exclusive production of arcyriaflavin A (5) and acceleration of turnover (8). One possibility to account for this phenomenon is that RebC can direct the outcome of the reaction by mediating the catalytic activity of StaP through a protein-protein interaction rather than acting catalytically itself. Although no stable interaction was found between StaP and RebC through pull-down assays (8), a transient complex cannot be ruled out. Another possibility...